Biomarin Pharma Expects $283M Pre-Tax Charges for IPR&D in Q3 2026
BioMarin Pharmaceutical Inc. anticipates pre-tax charges of $283 million in the third quarter of 2026, related to bought in-process research and development expenses.
BioMarin Pharmaceutical Inc. anticipates pre-tax charges of $283 million in the third quarter of 2026, related to bought in-process research and development expenses.